标题
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
作者
关键词
-
出版物
Journal of the National Comprehensive Cancer Network
Volume 20, Issue 9, Pages 972-980
出版商
Harborside Press, LLC
发表日期
2022-09-09
DOI
10.6004/jnccn.2022.0047
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
- (2022) David M Gershenson et al. LANCET
- The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes
- (2022) David M. Gershenson et al. GYNECOLOGIC ONCOLOGY
- Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer
- (2021) Claire Falandry et al. JAMA Oncology
- The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance
- (2020) Lauren P. Cobb et al. GYNECOLOGIC ONCOLOGY
- Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
- (2020) April K. S. Salama et al. JOURNAL OF CLINICAL ONCOLOGY
- MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
- (2020) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities
- (2020) Dane Cheasley et al. JOURNAL OF PATHOLOGY
- EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.
- (2019) Claire Falandry et al. JOURNAL OF CLINICAL ONCOLOGY
- Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics
- (2018) Jaime Prat et al. HUMAN PATHOLOGY
- Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study
- (2018) Frédéric Selle et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
- (2018) Lauren C Peres et al. JNCI-Journal of the National Cancer Institute
- Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
- (2018) Lauren C Peres et al. JNCI-Journal of the National Cancer Institute
- Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
- (2017) Amanda N. Fader et al. GYNECOLOGIC ONCOLOGY
- Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study
- (2017) Vivian E. von Gruenigen et al. GYNECOLOGIC ONCOLOGY
- Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
- (2017) David M. Gershenson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: Results of a pooled analysis of three GINECO phase II trials
- (2016) Fabien Tinquaut et al. GYNECOLOGIC ONCOLOGY
- Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials
- (2016) Dawn L. Hershman et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas
- (2014) Charlie Gourley et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
- (2014) Sandro Pignata et al. LANCET ONCOLOGY
- Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial
- (2013) C. Falandry et al. ANNALS OF ONCOLOGY
- New insights into ovarian cancer pathology
- (2012) J. Prat ANNALS OF ONCOLOGY
- Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
- (2012) David M. Gershenson et al. GYNECOLOGIC ONCOLOGY
- Recent progress in the diagnosis and treatment of ovarian cancer
- (2011) Danijela Jelovac et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Reclassification of serous ovarian carcinoma by a 2-tier system
- (2011) Diane C. Bodurka et al. CANCER
- Completion of Adjuvant Chemotherapy and Use of Health Services for Older Women With Epithelial Ovarian Cancer
- (2011) Kathleen M. Fairfield et al. JOURNAL OF CLINICAL ONCOLOGY
- Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
- (2011) Arti Hurria et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-grade serous carcinomas of the ovary contain very few point mutations
- (2011) Siân Jones et al. JOURNAL OF PATHOLOGY
- BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas
- (2010) Kwong-Kwok Wong et al. AMERICAN JOURNAL OF PATHOLOGY
- Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
- (2009) David M. Gershenson et al. GYNECOLOGIC ONCOLOGY
- A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer
- (2008) Sandro Pignata et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More